NeoStem, Inc. (Nasdaq: NBS), is a leader in the emerging cellular therapy market. Its business model includes the development of novel proprietary cell therapy products as well as operating a contract development and manufacturing organization (CDMO) that provides services to others in the regenerative medicine industry. This combination of a therapeutic development business and revenue-generating service provider business provides the Company with unique capabilities for cost effective in-house product development and immediate revenue and cash flow generation.
NeoStem is discovering the power of Stem Cell technology in wound care. Preliminary data in preclinical models of severe complex wounds suggests that human VSELs™ (very small embryonic like stem cells) accelerates wound healing. NeoStem hopes to advance into early clinical studies to assess therapeutic potential of VSEL technology.
Management is building the Company based on the foundation and sector expertise provided by its contract development and manufacturing subsidiary, Progenitor Cell Therapy (PCT). As a leader in the cell therapy industry in-process development innovation and cost effective scale-up, PCT supports NeoStem’s internal development of its therapeutic programs. Additionally, NeoStem’s pipeline of proprietary cell therapy products continues to develop and, most notably, the company is on track to complete enrollment of our PreSERVE Phase 2 clinical trial this year, investigating the Company’s most advanced product candidate, AMR-001, in preserving heart function after a severe heart attack, with data read out 6-8 months after the last patient is infused. NeoStem continues to advance its T cell program with the goal of developing treatments for immune-mediated diseases such as type 1 diabetes, and inflammatory conditions such as steroid resistant asthma. Finally, the company continues to develop our very small embryonic like stem cell (VSELTM Technology) platform in pre-clinical models and expect soon to advance into early clinical studies that assess the therapeutic potential of VSELTM Technology in wound care, bone regeneration and/or macular restoration.
Management believes that NeoStem is ideally positioned to be an integrated leader in the cell therapy industry. The company has significant research and development capabilities, manufacturing and processing facilities on both the East and West Coasts of the United States, as well as talented and experienced management and clinical teams. NeoStem’s investments in its therapeutic pipeline, which the company has approached with scientific discipline and business and market analysis, include significant opportunities which are protected by an expanding intellectual property portfolio, positioning the Company for dynamic partner collaborations.
For further information regarding NeoStem’s innovative ideas and its progress in advancing cellular therapy, be sure to attend the 7th Annual OneMedForum in San Francisco January 13th-15th.